AtTEnd: Atezolizumab plus Chemotherapy for Advanced or Recurrent Endometrial Cancer Last updated on Jun 8, 2026 Previous SOLO2/ENGOT-Ov21: Maintenance Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer (Final OS Analysis) Next PORTEC-4a: Molecular Profile-Based Adjuvant Treatment for High-Intermediate Risk Endometrial Cancer
